$CAPR News

Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy

Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy

HC Wainwright & Co. Downgrades Capricor Therapeutics to Neutral

'FDA panel votes against Capricor's Duchenne heart disease therapy'- Reuters

Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount

Capricor Stock Tanks On FDA AdCom Notes - What Investors Should Know

QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli (UPDATED)

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

Capricor Says FDA Briefing Relies On Obsolete Analysis Plan Ahead Of Deramiocel Advisory Committee Meeting For Duchenne Muscular Dystrophy BLA

Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents

FDA Staff Review Says Data For Co's Duchenne Cell Therapy Does Not Provide Substantial Evidence Of Effectiveness

Capricor Therapeutics Announces FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Intends To Call Advisory Committee Meeting To Discuss Capricor's BLA Of Deramiocel For Duchenne Muscular Dystrophy Treatment

Capricor Therapeutics To Present Data From Its Current HOPE-2 Open-Label Extension Trial Of Deramiocel For Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy 2026 Annual Conference

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date